CHICAGO AND SAN FRANCISCO–(BUSINESS WIRE)–Nov. 4, 2022–
SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION– Viz.ai, the leader in AI disease detection and intelligent care coordination, today announced the launch of a comprehensive cardiology suite to accelerate and improve patient access to cardiovascular treatments. innovative. Announced at the American Heart Association (AHA) Scientific Sessions, Viz Cardio Suite leverages AI disease detection, workflow optimization and care team coordination to improve the efficiency of cardiovascular care delivery.
This press release is multimedia. View the full press release here: https://www.businesswire.com/news/home/20221104005201/en/
Screenshots of Viz PE with RV/LV ratio data (left), along with the company’s ECG viewer (right). Both are part of the comprehensive Viz Cardio suite designed to accelerate and improve patient access to innovative cardiovascular treatments. Source: Viz.ai.
“Tools such as Viz Cardio Suite will identify patients with targeted cardiovascular diseases and ensure the right clinician is alerted and involved in patient care at the right time with the right therapy,” said Dr. Kenneth Rosenfield, Interventional Cardiologist, section chief of the vascular service. Medicine and Intervention at Massachusetts General Hospital. “In addition, the use of this latest technology will help neurology and cardiology care teams advance the heart-brain connection and improve the way we treat stroke as well as structural heart disease, fibrillation atrial and other debilitating heart conditions.”
Despite continued advances in diagnosis and therapy, heart disease remains the leading cause of death worldwide, largely due to late diagnosis or ineffective care pathways. With its Cardio Suite, Viz.ai streamlines care pathways by improving patient identification, developing disease-specific workflows, and connecting patients to the right provider in their medical journey.
“Viz.ai is rapidly becoming adopted in US healthcare systems as a system of action. The comprehensive Viz Cardio suite brings these capabilities to cardiovascular disease, where optimal patient outcomes often depend on achieving the right therapy by the patient,” said Chris Mansi, CEO of Viz.ai. “Not only does the Viz Cardio suite use AI to detect more diseases in more patients, it also speeds up the care journey . This can improve the quality of care for patients and the working practices of cardiologists, while increasing hospital revenues and reducing overall healthcare costs.
The Viz Cardio Suite extends Viz.ai’s leadership in cardiology beyond its FDA-cleared AI modules for Pulmonary Embolism (Viz PE), with an automated Right Ventricle/Left Ventricle (RV/ LV) and aortic disease (Viz AORTIC).
The Viz Cardio Suite also includes:
- Mobile ECG Viewer, which allows healthcare teams to:
- Quickly and easily access and view all 12-lead ECGs circulating in the healthcare system
- Compare ECGs to previous ones
- Share high-quality ECGs through a HIPAA-compliant app
- Mobile and web-based cardiac image viewer, which allows healthcare teams to save time and access images on the go
- Cardiology consultation in application
- Patient data acquisition via CVIS and EHR integration
- Comprehensive AI-structured echo reports in less than 2 minutes 1, in partnership with Us2.ai
1 Total time may vary depending on interpreting physician and imaging source.
About Viz.ai, Inc.
Viz.ai is pioneering the use of AI algorithms and machine learning to accelerate diagnosis and care, spanning over 200 million lives in more than 1,200 hospitals and healthcare systems across the United States and in Europe. The AI-powered Viz platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical point-of-care decisions, optimizes care pathways and helps improve outcomes . Powered by clinical data, the Viz platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information, visit viz.ai.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20221104005201/en/
CONTACT: Joe Duraes
Pazanga Health Communications for Viz.ai
jduraes@pazangahealth.com
+1-917-687-6419
KEYWORD: CALIFORNIA ILLINOIS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: APPS/APPLICATIONS TECHNOLOGY MEDICAL DEVICES HOSPITALS HEALTH TECHNOLOGY CARDIOLOGY RADIOLOGY HEALTH ARTIFICIAL INTELLIGENCE
SOURCE: Viz.ai, Inc.
Copyright BusinessWire 2022.
PUBLISHED: 11/04/2022 08:00 AM / DISK: 11/04/2022 08:02 AM
http://www.businesswire.com/news/home/20221104005201/en
Copyright BusinessWire 2022.